These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31155716)

  • 1. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia.
    Fadlallah J; Michel M; Crickx E; Limal N; Costedoat N; Malphettes M; Fieschi C; Galicier L; Oksenhendler E; Godeau B; Audia S; Mahévas M
    Br J Haematol; 2019 Oct; 187(1):124-128. PubMed ID: 31155716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia.
    Yao M; Zhang J; Li Y; Lv L; Jia L; Yang C; Huang Y; Liu H; Wang J; Chen M; Zhang H
    Medicine (Baltimore); 2022 Jan; 101(4):e28679. PubMed ID: 35089216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.
    Piatek CI; Bocian H; Algaze S; Weitz IC; O'Connell C; Liebman HA
    Acta Haematol; 2020; 143(3):244-249. PubMed ID: 31665725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type.
    Meyer O; Stahl D; Beckhove P; Huhn D; Salama A
    Br J Haematol; 1997 Sep; 98(4):860-2. PubMed ID: 9326179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation.
    Wong D; Thomas W; Butler A; Sharkey L
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33980556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab.
    Neave L; Wilson AJ; Lissack M; Scully M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome.
    Gao XM; Yu YY; Zhao H; Cai H; Zhang L; Cao XX; Zhou DB; Li J
    Ann Hematol; 2021 Nov; 100(11):2755-2761. PubMed ID: 34331562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia.
    Chen M; Zhuang J; Yang C; Zhang L; Wang W; Cai H; Yu Y; Li J; Zhou D; Han B
    Ann Hematol; 2020 May; 99(5):1141-1143. PubMed ID: 32144437
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura.
    Howard J; Hoffbrand AV; Prentice HG; Mehta A
    Br J Haematol; 2002 Jun; 117(3):712-5. PubMed ID: 12028047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in the treatment of autoimmune haemolytic anaemia.
    Rodrigo C; Rajapakse S; Gooneratne L
    Br J Clin Pharmacol; 2015 May; 79(5):709-19. PubMed ID: 25139610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
    Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
    Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.